The Global Biopharmaceutical And Biomedicine Market Growth Accelerated By Advancements In Technology
The biopharmaceutical and biomedicine industry involves the research, development, testing, manufacturing and distribution of biopharmaceuticals and biologics. Biologics and pharmaceuticals derived through biological sources and processes play a pivotal role in treatment of various diseases. The industry focuses on developing novel therapies for cancer, autoimmune disorders, infectious diseases and other chronic ailments. There is notable progress in fields of gene and cell therapy, tissue engineering and regenerative medicine. Advances in bioprocessing technologies and recombinant DNA techniques have enabled large scale production of vaccines, blood components and monoclonal antibodies. The global biopharmaceutical and biomedicine market is estimated to be valued at US$ 20025.57 Bn or Mn in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Rising prevalence of chronic diseases such as cancer, cardiovascular ailments, diabetes and neurological disorders globally has resulted in increased demand for biopharmaceuticals. According to World Health Organization, chronic diseases accounted for approximately 60% of the global deaths in 2021. Biologic medicines derived from living systems are indispensable for treatment of various life-threatening and debilitating conditions. The growing geriatric population prone to chronic health issues also supports growth of this market. Moreover, availability of biosimilars and tremendous progress in fields of gene therapy and regenerative medicines are other key drivers bolstering the market growth. However, high costs of biopharmaceutical R&D and regulatory approvals remain a major challenge. Stringent policies for biosimilar approval delays market entry of affordable biologics as well.
SWOT Analysis
Strength: The biopharmaceutical and biomedicine market relies on innovation and emerging technologies. R&D continues to discover new treatments and cures. Many biotech firms collaborate with universities and research institutions to advance scientific knowledge. Patient outcomes have greatly improved due to biologic drugs and regenerative medicine.
Weakness: Developing new drugs requires huge investments of capital and time. Failure rates are high as most candidates do not make it through clinical trials. Manufacturing biologics at large scales is complex and costly. Consolidation in the sector leads to fewer competitors developing niche therapies.
Opportunity: Rising chronic disease burden globally drives demand for specialized biologic therapies. Personalized medicine tailors treatments to individual genetics and biomarkers. Regenerative therapies could transform care for diseases currently considered incurable. Emerging nations offer large patient populations and lucrative markets.
Threats: Stringent regulations pose development and market access challenges. Biosimilars erode brand drug revenues after patent expirations. Healthcare reforms pressure pricing and reimbursement. Geopolitical tensions disrupt supply chains for raw materials and manufacturing. Natural disasters or pandemics disrupt operations.
Key Takeaways
The Global Biopharmaceutical and Biomedicine Market Demand is expected to witness high growth. Regional analysis shows that North America currently dominates due to spending power and concentration of R&D activity in the US and Canada. However, Asia Pacific is growing fastest as nations like China and India invest heavily to serve local demand and become innovation hubs.
Key players operating in the biopharmaceutical and biomedicine market are KABA Group, Yubico, SecuGen Corporation, Anviz Global, Nitgen Co., Ltd., Integrated Biometrics, BIO-key International, Daon Inc., Suprema Inc., Integrated Biometrics, ASSA ABLOY, Dormakaba Holding, Allegion plc, HID Global Corporation, Gunnebo Security Group, IDenticard Systems, PrimeKey Solutions AB, Thales Group, Gemalto NV, NXP Semiconductors N.V.. Collaborations are frequent as alliances help mitigate risks and costs. Mergers and acquisitions see large firms acquire smaller innovative biotechs to gain new product lines and capabilities.
The global biopharmaceutical and biomedicine market is expected to witness high growth. Regional analysis shows that North America currently dominates due to spending power and concentration of R&D activity in the US and Canada. However, Asia Pacific is growing fastest as nations like China and India invest heavily to serve local demand and become innovation hubs.
Get More Insights Here
Comments
0 comment